CoChat

Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model

Open access
Hinterleitner, Reinhard, Gruber, Thomas, Pfeifhofer-Obermair, Christa, Lutz-Nicoladoni, Christina, Tzankov, Alexander, Schuster, Manfred, Penninger, Josef M., Loibner, Hans, Lametschwandtner, Günther, Wolf, Dominik, Baier, Gottfried · 2012 · PLoS ONE

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Abstract

The ubiquitin ligase Cbl-b is an established regulator of T cell immune response thresholds. We recently showed that adoptive cell transfer (ACT) of cblb(-/-) CD8(+) T cells enhances dendritic cell (DC) immunization-mediated anti-tumor effects in immune-competent recipients. However, translation of cblb targeting to clinically applicable concepts requires that inhibition of cblb activity be transient and reversible. Here we provide experimental evidence that inhibition of cblb using chemically synthesized siRNA has such potential. Silencing cblb expression by ex vivo siRNA transfection of polyclonal CD8(+) T cells prior to ACT increased T cell tumor infiltration, significantly delayed tumor outgrowth, and increased survival rates of tumor-bearing mice. As shown by ex vivo recall assays, cblb silencing resulted in significant augmentation of intratumoral T cell cytokine response. ACT of cblb-silenced polyclonal CD8(+) T cells combined with DC-based tumor vaccines predominantly mediated anti-tumor immune responses, whereas no signs of autoimmunity could be detected. Importantly, CBLB silencing in human CD8(+) T cells mirrored the effects observed for cblb-silenced and cblb-deficient murine T cells. Our data validate the concept of enhanced anti-tumor immunity by repetitive ACT of ex vivo cblb siRNA-silenced hyper-reactive CD8(+) T cells as add-on adjuvant therapy to augment the efficacy of existing cancer immunotherapy regimens in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0044295

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cblb knockdown in CD8+ T cells confers resistance to the inhibitory effects of TGFβ. Mouse CD8+ T cells were nucleofected with cblb siRNA or control siRNA and stimulated with anti-CD3 and anti-CD28 in the presence or absence of TGFβ. The production of IFNγ by CD8+ T cells was efficiently suppressed by exposure to TGFβ while cblb knockdown cells still produced high levels of IFNγ. (A) Silencing efficacy of cblb siRNA was analyzed by immunoblotting. (B) Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. IFNγ levels of each group without TGFβ were set 100%. Means ± SEM of three independent experiments are shown.
Figure 1 Cblb knockdown in CD8+ T cells confers resistance to the inhibitory effects of TGFβ. Mouse CD8+ T cells were nucleofected with cblb siRNA or control siRNA and stimulated with anti-CD3 and anti-CD28 in the presence or absence of TGFβ. The production of IFNγ by CD8+ T cells was efficiently suppressed by exposure to TGFβ while cblb knockdown cells still produced high levels of IFNγ. (A) Silencing efficacy of cblb siRNA was analyzed by immunoblotting. (B) Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. IFNγ levels of each group without TGFβ were set 100%. Means ± SEM of three independent experiments are shown.CC BY · PubMed Central
Figure 2 ACT of polyclonal cblb-silenced T cells reduces tumor growth rates in vivo. (A) Tumor therapy schedule. Wild type mice s.c. injected with 1×105 B16ova cells were vaccinated with (B-F) SIINFEKL-pulsed DCs or (G) gp100-pulsed DCs on days 6 and 13. Twenty-four hours after DC vaccination, either control or cblb siRNA nucleofected polyclonal CD8+ T cells (5×106) were i.v. injected into tumor bearing mice. (B) Tumor growth of untreated mice, (C) DC vaccinated mice, (D) mice treated with DCs plus control-siRNA nucleofected CD8+ T cells, and (E) DCs plus cblb siRNA silenced CD8+ T cells are shown. Tumor volume was measured every second day. Representative results out of two independent experiments are shown (n = 7 - 12 mice per group). (F) Survival of the animals described in (B–E) was monitored and the respective Kaplan-Maier curves are given. p = 0.03 (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA). (G) Survival of B16ova-challenged wild type mice treated as in (B-E) but vaccinated with gp100-pulsed DCs. Respective Kaplan-Maier curves are given (n = 3 - 4 mice per group).
Figure 2 ACT of polyclonal cblb-silenced T cells reduces tumor growth rates in vivo. (A) Tumor therapy schedule. Wild type mice s.c. injected with 1×105 B16ova cells were vaccinated with (B-F) SIINFEKL-pulsed DCs or (G) gp100-pulsed DCs on days 6 and 13. Twenty-four hours after DC vaccination, either control or cblb siRNA nucleofected polyclonal CD8+ T cells (5×106) were i.v. injected into tumor bearing mice. (B) Tumor growth of untreated mice, (C) DC vaccinated mice, (D) mice treated with DCs plus control-siRNA nucleofected CD8+ T cells, and (E) DCs plus cblb siRNA silenced CD8+ T cells are shown. Tumor volume was measured every second day. Representative results out of two independent experiments are shown (n = 7 - 12 mice per group). (F) Survival of the animals described in (B–E) was monitored and the respective Kaplan-Maier curves are given. p = 0.03 (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA). (G) Survival of B16ova-challenged wild type mice treated as in (B-E) but vaccinated with gp100-pulsed DCs. Respective Kaplan-Maier curves are given (n = 3 - 4 mice per group).CC BY · PubMed Central
Figure 3 cblb silencing substantially enhances tumor infiltration of T cells. Flow cytometric analysis of tumor-infiltrating lymphocytes 7 days (A, B, D, E) or 4 days (C) after a single ACT in combination with DC vaccination into wild type mice was performed. (A) CD8+ T cell infiltrates gated on whole tumor, (B) CD8+ T cell infiltrates gated on total CD45+ leukocytes, (C) SIINFEKL-specific infiltrates gated on CD8+ cells (D) CD4+CD25- T cell infiltrates and (E) CD4+CD25+ T cell infiltrates gated on total CD45+ leukocytes are shown. Means ± SEM of two independent experiments are shown (n = 7 - 8 mice per group). (A) p = 0.06 (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA) (B-E) n.s. (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA).
Figure 3 cblb silencing substantially enhances tumor infiltration of T cells. Flow cytometric analysis of tumor-infiltrating lymphocytes 7 days (A, B, D, E) or 4 days (C) after a single ACT in combination with DC vaccination into wild type mice was performed. (A) CD8+ T cell infiltrates gated on whole tumor, (B) CD8+ T cell infiltrates gated on total CD45+ leukocytes, (C) SIINFEKL-specific infiltrates gated on CD8+ cells (D) CD4+CD25- T cell infiltrates and (E) CD4+CD25+ T cell infiltrates gated on total CD45+ leukocytes are shown. Means ± SEM of two independent experiments are shown (n = 7 - 8 mice per group). (A) p = 0.06 (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA) (B-E) n.s. (DC+CD8+ cblb siRNA versus DC+CD8+ control siRNA).CC BY · PubMed Central
Figure 4 Enhanced cytokine recall responses of cblb-silenced CD8+ T cell tumor infiltrates. Tumor infiltrating CD8+ T cells either nucleofected with control siRNA or cblb siRNA were ex vivo stimulated with unloaded or SIINFEKL loaded DCs and (A) IL-2 as well as (B) IFNγ secretion was measured by BioPlex technology. Means ± SEM of four independent experiments are shown. (A) p = 0.03 (SIINFEKL loaded DC+CD8+ cblb siRNA versus SIINFEKL loaded DC+CD8+ control siRNA), (B) p = 0.05 (SIINFEKL loaded DC+CD8+ cblb siRNA versus SIINFEKL loaded DC+CD8+ control siRNA).
Figure 4 Enhanced cytokine recall responses of cblb-silenced CD8+ T cell tumor infiltrates. Tumor infiltrating CD8+ T cells either nucleofected with control siRNA or cblb siRNA were ex vivo stimulated with unloaded or SIINFEKL loaded DCs and (A) IL-2 as well as (B) IFNγ secretion was measured by BioPlex technology. Means ± SEM of four independent experiments are shown. (A) p = 0.03 (SIINFEKL loaded DC+CD8+ cblb siRNA versus SIINFEKL loaded DC+CD8+ control siRNA), (B) p = 0.05 (SIINFEKL loaded DC+CD8+ cblb siRNA versus SIINFEKL loaded DC+CD8+ control siRNA).CC BY · PubMed Central
Figure 5 No overt morphological signs of autoimmunity in mice treated with cblb-silenced CD8+ T cells. B16ova tumor bearing mice were treated twice with SIINFEKL-pulsed DCs plus CD8+ T cells either nucleofected with cblb- or control-siRNA. Animals were sacrificed when tumor length reached 2 cm. Histological sections of paraffin-embedded organs (skin, lung, spleen, pancreas, liver, and kidney) were stained with hematoxylin-eosin (HE) to analyze morphological signs of autoimmunity as well as immune cell infiltrates (n = 4) by an experienced pathologist in a blinded fashion.
Figure 5 No overt morphological signs of autoimmunity in mice treated with cblb-silenced CD8+ T cells. B16ova tumor bearing mice were treated twice with SIINFEKL-pulsed DCs plus CD8+ T cells either nucleofected with cblb- or control-siRNA. Animals were sacrificed when tumor length reached 2 cm. Histological sections of paraffin-embedded organs (skin, lung, spleen, pancreas, liver, and kidney) were stained with hematoxylin-eosin (HE) to analyze morphological signs of autoimmunity as well as immune cell infiltrates (n = 4) by an experienced pathologist in a blinded fashion.CC BY · PubMed Central
Figure 6 siRNA-mediated silencing of human CBLB is effective and leads to hyper-responsiveness of CD8+ T cells. Human CD8+ T cells were nucleofected with CBLB siRNA #10 or control siRNA and stimulated with anti-CD3 and anti-CD28 as indicated. Similar results were obtained with non-overlapping siRNA oligonucleotide #11 (not shown). (A) Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. Means ± SEM of two independent experiments are shown. p = 0.01 (CD8+ CBLB siRNA versus CD8+ control siRNA, double stimulated). (B) Human CD8+ T cells were nucleofected with CBLB siRNA or control siRNA and stimulated with anti-CD3 and anti-CD28 in the presence or absence of TGFβ. Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. IFNγ levels of each group without TGFβ were set 100%. Representative results of two independent experiments are shown. Silencing efficacy of cblb siRNA was analyzed by (A) immunoblotting (One experiment representative of three experiments is shown) or (C) qRT-PCR. Means ± SEM of two independent experiments are shown.
Figure 6 siRNA-mediated silencing of human CBLB is effective and leads to hyper-responsiveness of CD8+ T cells. Human CD8+ T cells were nucleofected with CBLB siRNA #10 or control siRNA and stimulated with anti-CD3 and anti-CD28 as indicated. Similar results were obtained with non-overlapping siRNA oligonucleotide #11 (not shown). (A) Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. Means ± SEM of two independent experiments are shown. p = 0.01 (CD8+ CBLB siRNA versus CD8+ control siRNA, double stimulated). (B) Human CD8+ T cells were nucleofected with CBLB siRNA or control siRNA and stimulated with anti-CD3 and anti-CD28 in the presence or absence of TGFβ. Supernatants were taken two days post-transfection and the amount of IFNγ secreted was measured by BioPlex technology. IFNγ levels of each group without TGFβ were set 100%. Representative results of two independent experiments are shown. Silencing efficacy of cblb siRNA was analyzed by (A) immunoblotting (One experiment representative of three experiments is shown) or (C) qRT-PCR. Means ± SEM of two independent experiments are shown.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 65

Metadata

Authors
Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., & Baier, G.
Affiliations
  • Innsbruck Medical University (AT)
  • Apeiron Biologics (Austria) (AT)
  • Institute of Molecular Biotechnology (AT)
  • University of Bonn (DE)
Corresponding author
Baier, Gottfried
Venue
PLoS ONE
Published
2012-09-04
Volume
7
Issue
9
Pages
e44295
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2009329366
Cited by
59
References
39
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 11 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 7
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Austrian Federal Ministry of Economy, Family and Youth
  • Austrian Science Fund (SFB021, P 22207)
  • Bundesministerium für Verkehr, Innovation und Technologie
  • Standortagentur Tirol
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
Cbl-b, siRNA knockdown, CD8+ T cells, adoptive cell transfer, dendritic cell vaccine, B16 melanoma, cancer immunotherapy, T cell activation threshold, ubiquitin ligase, ex vivo T cell engineering, tumor-infiltrating T cells, cytokine response, autoimmunity
MeSH terms
Animals, Dendritic Cells, Female, Humans, Melanoma, Experimental, Mice, Inbred C57BL, Skin Neoplasms, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, Adoptive Transfer, Cancer Vaccines, Gene Silencing, RNA, Small Interfering, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-cbl, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model. https://app.cochat.ai/papers/10.1371/journal.pone.0044295
The paper
Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., & Baier, G. (2012). Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model. PLoS ONE. https://doi.org/10.1371/journal.pone.0044295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.